Law360, New York (May 18, 2015, 6:25 PM EDT) -- Celyad SA laid the groundwork Monday to access the U.S. public market, filing with regulators to raise $115 million in an initial public offering and a concurrent private offering as the cardiovascular disease and oncology treatment developer looks to fund clinical trials.
Belgium-based Celyad, formerly known as Cardio3 Biosciences SA, has not yet disclosed how many shares it plans to sell in the IPO and the concurrent private placement, but it did indicate that it plans to list its American depositary shares on the Nasdaq under the symbol "CYAD," according to the prospectus.
The biotech’s shares are already listed on the...
Stay ahead of the curve
In the legal profession, information is the key to success.
You have to know what’s happening with clients, competitors, practice areas, and industries.
The Secret Pre-IPO Market
Law360 provides the intelligence you need to remain an expert and beat the competition.
- Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
- Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
- Create custom alerts for specific article and case topics and so much more!
TRY LAW360 FREE FOR SEVEN DAYS